Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sanifit Therapeutics S A is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter indicates a highly focused prosecution phase for the company's intellectual property. The firm is currently working to resolve this outstanding action to advance its application toward allowance.
The portfolio is reviewed by 1 distinct examiner and 1 distinct art unit. This structure shows that the company's current work is concentrated within a specific technical department. Practitioners can expect a consistent examination environment, as there is no variation in the personnel or departmental standards currently being applied to the portfolio.
STOCKTON, LAURA LYNNE is the busiest examiner for this company. This examiner is responsible for the 1 busiest examiner pending office action. Since STOCKTON, LAURA LYNNE handles the only active matter, the outcome of the entire pending portfolio depends on the interaction with this single individual. The concentration of work under STOCKTON, LAURA LYNNE allows for a focus on this examiner's specific requirements and historical patterns.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOCKTON, LAURA LYNNE | 1 | 75.3% | +33.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18274805 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | STOCKTON, LAURA LYNNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18274805 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | STOCKTON, LAURA LYNNE | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18274805 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | STOCKTON, LAURA LYNNE | 1626 | §102§112Other | Final Rejection | — | Pending | Jul 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSanifit Therapeutics S A has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Laura Lynne Stockton has the most, with 1 of Sanifit Therapeutics S A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
